Second assessment of NeuroAIDS in Africa

References

• Aaron L, Saadoun D, Calatroni I, Launay O, Memain N, Vincent V, Marchal G, Dupont B, Bouchaud O, Valeyre D, Lortholary O. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004; 10: 388–398
   PubMed Web of Science ®Google Scholar
• Amod F. AIDS associated toxoplasmosis. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Antinori A, Cingolani A, Giancola M L, Forbici F, De Luca A, Perno C F. Clinical implications of HIV-1 drug resistance in the neurological compartment. Scand J Infect Dis Suppl 2003; 35(Suppl 106)41–44
   Google Scholar
• Belman A L, Diamond G, Dickson D, Horoupian D, Llena J, Lantos G, Rubinstein A. Pediatric acquired immunodeficiency syndrome. Neurologic syndromes. Am J Dis Child 1988; 142: 29–35
   PubMedGoogle Scholar
• Boffito M, Pillay D, Wilkins E. Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. Int J Clin Pract 2006; 60: 1098–1106
   Google Scholar
• Bonnet F, Bonarek M, Morlat P, Mercie P, Dupon M, Gemain M C, Malvy D, Bernard N, Pellegrin J L, Beylot J. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis 2003; 36: 1324–1328
   PubMed Web of Science ®Google Scholar
• Bottieau E, Noe A, Florence E, Colebunders R. Multiple tuberculous brain abscesses in an HIV-infected patient successfully treated with HAART and antituberculous treatment. Infection 2003; 31: 118–120
   Google Scholar
• Breen R A, Swaden L, Ballinger J, Lipman M C. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 2006; 66: 2299–2308
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr 2005; 24: 5–15
   PubMed Web of Science ®Google Scholar
• Cashion M F, Banks W A, Bost K L, Kastin A J. Transmission routes of HIV-1 gp120 from brain to lymphoid tissues. Brain Res 1999; 822: 26–33
   Google Scholar
• Childs E A, Lyles R H, Selnes O A, Chen B, Miller E N, Cohen B A, Becker J T, Mellors J, McArthur J C. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52: 607–613
   PubMed Web of Science ®Google Scholar
• Clements J E. The SIV macaque model of HIV CNS disease. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Clements J E, Li M, Gama L, Bullock B, Carruth L M, Mankowski J L, Zink M C. The central nervous system is a viral reservoir in simian immunodeficiency virus–infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J NeuroVirol 2005; 11: 180–189
   PubMed Web of Science ®Google Scholar
• Clifford D B. Ethiopian NeuroAIDS assessment. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Clifford D B, Mitike M T, Mekonnen Y, Zhang J, Zenebe G, Melaku Z, Zewde A, Gessesse N, Wolday D, Messele T, Teshome M, Evans S. Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. J NeuroVirol 2007; 13: 67–72
   PubMed Web of Science ®Google Scholar
• Coghlan M E, Sommadossi J P, Jhala N C, Many W J, Saag M S, Johnson V A. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33: 1914–1921
   PubMed Web of Science ®Google Scholar
• Cysique L A, Maruff P, Brew B J. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J NeuroVirol 2004; 10: 350–357
   PubMed Web of Science ®Google Scholar
• Cysique L A, Maruff P, Brew B J. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006; 66: 1447–1450
   PubMed Web of Science ®Google Scholar
• Dabis F, Ekpini E R. HIV-1/AIDS and maternal and child health in Africa. Lancet 2002; 359: 2097–2104
   PubMed Web of Science ®Google Scholar
• Dean G L, Edwards S G, Ives N J, Matthews G, Fox E F, Navaratne L, Fisher M, Taylor G P, Miller R, Taylor C B, de Ruiter A, Pozniak A L. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75–83
   PubMed Web of Science ®Google Scholar
• Eggers C, Hertogs K, Sturenburg H J, van Lunzen J, Stellbrink H J. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003; 17: 1897–1906
   PubMed Web of Science ®Google Scholar
• Ellis R J, Hsia K, Spector S A, Nelson J A, Heaton R K, Wallace M R, Abramson I, Atkinson J H, Grant I, McCutchan J A. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42: 679–688
   PubMed Web of Science ®Google Scholar
• Enting R H, Hoetelmans R M, Lange J M, Burger D M, Beijnen J H, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998; 12: 1941–1955
   PubMed Web of Science ®Google Scholar
• Epstein L G, Sharer L R, Oleske J M, Connor E M, Goudsmit J, Bagdon L, Robert-Guroff M, Koenigsberger M R. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics 1986; 78: 678–687
   PubMed Web of Science ®Google Scholar
• Evans S. Assessment of NeuroAIDS in Africa: statistical issues and design. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• FDA. d4T and lactic acidosis with neuromuscular weakness: FDA warning. AIDS Treat News 2002; 378: 5–6
   Google Scholar
• Ferrando S J, Rabkin J G, van Gorp W, Lin S H, McElhiney M. Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci 2003; 15: 208–214
   PubMed Web of Science ®Google Scholar
• Gabuzda D H, Hirsch M S. Neurologic manifestations of infection with human immunodeficiency virus. Clinical features and pathogenesis. Ann Intern Med 1987; 107: 383–391
   PubMed Web of Science ®Google Scholar
• Hakim J. Epidemiology of HIV in Africa. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Hall C. HIV associated dementia in the HAART era. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Herzmann C, Johnson M A, Youle M. Long-term effect of acetyl-l-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials 2005; 6: 344–50
   PubMed Web of Science ®Google Scholar
• Holding P. Pediatric neuroassessment in Kenya: children exposed to multiple risks. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Hosseinipour M. Lactic acidosis and ascending neuromuscular syndrome. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Imhof A, Ledergerber B, Gunthard H F, Haupts S, Weber R. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?. Clin Infect Dis 2005; 41: 721–728
   PubMed Web of Science ®Google Scholar
• Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C, Whitworth J. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185: 1244–1250
   PubMed Web of Science ®Google Scholar
• Kaleebu P, Nankya I L, Yirrell D L, Shafer L A, Kyosiimire-Lugemwa J, Lule D B, Morgan D, Beddows S, Weber J, Whitworth J A. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45: 28–33
   PubMed Web of Science ®Google Scholar
• Kanki P J, Hamel D J, Sankale J L, Hsieh C, Thior I, Barin F, Woodcock S A, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, Essex M ESMB. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179: 68–73
   PubMed Web of Science ®Google Scholar
• Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell J E, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005; 111: 194–213
   PubMed Web of Science ®Google Scholar
• Lalloo U. CNS TB. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Langford T D, Letendre S L, Larrea G J, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003; 13: 195–210
   PubMed Web of Science ®Google Scholar
• Liner K J, 2nd, Hall C D, Robertson K R. Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J NeuroVirol 2007; 13: 291–304
   PubMed Web of Science ®Google Scholar
• Lobato M N, Caldwell M B, Ng P, Oxtoby M J. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium. J Pediatr 1995; 126: 710–715
   PubMed Web of Science ®Google Scholar
• Marra C M. Neurosyphilis. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• McArthur J C, McClernon D R, Cronin M F, Nance-Sproson T E, Saah A J, St. Clair M, Lanier E R. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42: 689–698
   PubMed Web of Science ®Google Scholar
• Merry C. Antiretroviral rollout in Africa. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Mielke J. Peripheral nerve disease in HIV-infected subjects. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Moore R D, Wong W M, Keruly J C, McArthur J C. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000; 14: 273–278
   PubMed Web of Science ®Google Scholar
• Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, Gerits P, Ryan E, Yakoushina T, Khan S, Mahboob R, Naseer M, Dorfman D, Sharp V. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 61: 546–551
   PubMed Web of Science ®Google Scholar
• Moyle G J, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard B G. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16: 1341–1349
   PubMed Web of Science ®Google Scholar
• Nakasujja N. HIV/AIDS and the use of HAART in Uganda. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Neuenburg J K, Brodt H R, Herndier B G, Bickel M, Bacchetti P, Price R W, Grant R M, Schlote W. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171–177
   PubMed Web of Science ®Google Scholar
• Newton C. The definition of HIV encephalopathy in children living in Africa. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Osio M, Muscia F, Zampini L, Nascimbene C, Mailland E, Cargnel A, Mariani C. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst 2006; 11: 72–76
   PubMedGoogle Scholar
• Robertson K, Fiscus S, Kapoor C, Robertson W, Schneider G, Shepard R, Howe L, Silva S, Hall C. CSF, plasma viral load and HIV associated dementia. J NeuroVirol 1998; 4: 90–94
   Web of Science ®Google Scholar
• Robertson K R, Robertson W T, Ford S, Watson D, Fiscus S, Harp A G, Hall C D. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004; 36: 562–566
   PubMed Web of Science ®Google Scholar
• Saavedra-Lozano J, Ramos J T, Sanz F, Navarro M L, de Jose M I, Martin-Fontelos P, Mellado M J, Leal J A, Rodriguez C, Luque I, Madison S J, Irlbeck D, Lanier E R, Ramilo O. Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy. Pediatr Infect Dis J 2006; 25: 1142–1152
   Google Scholar
• Sacktor N. Assessment of HIV dementia in Uganda: results from the Academic Alliance Cohort. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Sacktor N, Nakasujja N, Robertson K, Clifford D B. HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of clade diversity. Nat Clin Pract Neurol 2007; 3: 436–443
   Google Scholar
• Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, Ronald A, Katabira E. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 2006; 67: 311–314
   PubMed Web of Science ®Google Scholar
• Sacktor N C, Skolasky R L, Lyles R H, Esposito D, Selnes O A, McArthur J C. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J NeuroVirol 2000; 6: 84–88
   Web of Science ®Google Scholar
• Schifitto G, McDermott M P, McArthur J C, Marder K, Sacktor N, Epstein L, Kieburtz K. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002; 58: 1764–1768
   PubMed Web of Science ®Google Scholar
• Sevigny J J, Albert S M, McDermott M P, McArthur J C, Sacktor N, Conant K, Schifitto G, Selnes O A, Stern Y, McClernon D R, Palumbo D, Kieburtz K, Riggs G, Cohen B, Epstein L G, Marder K. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63: 2084–2090
   PubMed Web of Science ®Google Scholar
• Shanbhag M C, Rutstein R M, Zaoutis T, Zhao H, Chao D, Radcliffe J. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy. Arch Pediatr Adolesc Med 2005; 159: 651–656
   PubMed Web of Science ®Google Scholar
• Simpson D M, Kitch D, Evans S R, McArthur J C, Asmuth D M, Cohen B, Goodkin K, Gerschenson M, So Y, Marra C M, Diaz-Arrastia R, Shriver S, Millar L, Clifford D B. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006; 66: 1679–1687
   PubMed Web of Science ®Google Scholar
• Stankoff B, Calvez V, Suarez S, Bossi P, Rosenblum O, Conquy L, Turell E, Dubard T, Coutellier A, Baril L, Bricaire F, Lacomblez L, Lubetzki C. Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment. Eur J Neurol 1999; 6: 669–675
   Google Scholar
• Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori M F, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007; 45: 174–182
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau F M, De Felici A, Benedetto A. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999; 13: 1889–1897
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Galgani S, Narciso P, Sampaolesi A, Antinori A, Giulianelli M, Serraino D, Ippolito G. Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr 2001; 28: 19–27
   PubMed Web of Science ®Google Scholar
• Traore M. Mali and NeuroAIDS. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Van Rie A. Kinshasa, Congo and children with HIV. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar
• Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, Fawzi W, Hunter D. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42: 843–852
   PubMed Web of Science ®Google Scholar
• Wynn H E, Brundage R C, Fletcher C V. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002; 16: 595–609
   PubMed Web of Science ®Google Scholar
• Zink M C. Impact of minocycline on SIV CNS and PNS disease. Second Assessment of NeuroAIDS in Africa: Arusha, Tanzania. 2006
   Google Scholar